We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ocular Sciences (OCLR)
OCLR 8.2600.0%Dec 10 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Alan Villalon who wrote (7)6/8/1999 2:47:00 PM
From: EyeDrMike  Read Replies (1) of 36
•1:06 Shares of Ocular Sciences shed nearly one-quarter of their value on trading that was more than 10 times heavier than average. (See other stocks with price and volume gaps.) John Kinnard analyst Richard Leza said he's hearing concerns that the maker of contact lenses (OCLR: news, msgs) will report lower-than-expected sales. He expects Ocular Sciences to show revenue of $47 million, but added some traders say the company may only do $45 million. The South San Francisco-based company declined comment. Shares of Ocular Science fell 6 3/8, or 23 percent, to 20 78.

This said, i bought back in today on the drop, after recently selling based on the introduction of ACUVUE 2 into the marketplace.

At this level, OCLR is a strong buy. IMO.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext